Wedbush Issues Pessimistic Forecast for KNSA Earnings

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) – Research analysts at Wedbush cut their FY2025 earnings per share (EPS) estimates for shares of Kiniksa Pharmaceuticals International in a research report issued to clients and investors on Tuesday, October 28th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.88 for the year, down from their prior estimate of $1.30. Wedbush has a “Outperform” rating and a $48.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals International’s current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals International’s Q4 2025 earnings at $0.27 EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.29 EPS, Q3 2026 earnings at $0.32 EPS, Q4 2026 earnings at $0.35 EPS, FY2026 earnings at $1.22 EPS, FY2027 earnings at $1.67 EPS and FY2028 earnings at $2.10 EPS.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, November 4th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). The firm had revenue of $180.85 million during the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business’s revenue was up 61.2% on a year-over-year basis. During the same period last year, the business earned ($0.18) earnings per share.

Other equities analysts have also recently issued reports about the stock. Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. The Goldman Sachs Group lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 25th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.29.

Kiniksa Pharmaceuticals International Stock Performance

Kiniksa Pharmaceuticals International stock opened at $37.29 on Thursday. The company has a 50 day moving average price of $36.85 and a 200 day moving average price of $30.95. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $42.05. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of 82.87 and a beta of 0.16.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 50,490 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $38.87, for a total value of $1,962,546.30. Following the completion of the sale, the chief accounting officer owned 27,046 shares of the company’s stock, valued at approximately $1,051,278.02. The trade was a 65.12% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Thomas Malley sold 78,233 shares of the business’s stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $415,147.14. The trade was a 86.18% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 905,398 shares of company stock worth $32,347,674. 53.48% of the stock is owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several large investors have recently added to or reduced their stakes in KNSA. EverSource Wealth Advisors LLC grew its position in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after purchasing an additional 568 shares in the last quarter. Osaic Holdings Inc. bought a new stake in Kiniksa Pharmaceuticals International in the second quarter worth $31,000. USA Financial Formulas bought a new stake in Kiniksa Pharmaceuticals International in the third quarter worth $32,000. Finally, US Bancorp DE bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $33,000. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.